Shenzhen Edge Medical FY2025 operating loss narrows 59.4% to RMB89 million; revenue more than doubled to RMB456 million

Reuters03-27

Shenzhen Edge Medical FY2025 operating loss narrows 59.4% to RMB89 million; revenue more than doubled to RMB456 million

Edge Medical published an annual results announcement, reporting revenue of RMB455.7 million and gross profit of RMB300.7 million.
Revenue more than tripled by 184.8%, which the company attributed to rapid growth in surgical robot sales in domestic and overseas markets.
Gross margin was 66.0%, up 4.7 percentage points, reflecting cost management and improved production efficiency.
Loss attributable to equity shareholders was RMB88.6 million, narrowing by 59.4%, driven mainly by higher sales volume of the Edge Multi-Port Endoscopic Surgical Robot.
Adjusted net loss was RMB20.5 million, narrowing by 88.5%, while cash and cash equivalents were RMB86.0 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Edge Medical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260327-12075247), on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622732518?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 23:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622732518","market":"nz","top_or_hot":-1,"title":"Shenzhen Edge Medical FY2025 operating loss narrows 59.4% to RMB89 million; revenue more than doubled to RMB456 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Shenzhen Edge Medical FY2025 operating loss narrows 59.4% to RMB89 million; revenue more than doubled to RMB456 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Edge Medical published an annual results announcement, reporting revenue of RMB455.7 million and gross profit of RMB300.7 million.\n        </li>\n<li>\n          Revenue more than tripled by 184.8%, which the company attributed to rapid growth in surgical robot sales in domestic and overseas markets.\n        </li>\n<li>\n          Gross margin was 66.0%, up 4.7 percentage points, reflecting cost management and improved production efficiency.\n        </li>\n<li>\n          Loss attributable to equity shareholders was RMB88.6 million, narrowing by 59.4%, driven mainly by higher sales volume of the Edge Multi-Port Endoscopic Surgical Robot.\n        </li>\n<li>\n          Adjusted net loss was RMB20.5 million, narrowing by 88.5%, while cash and cash equivalents were RMB86.0 million.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Edge Medical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260327-12075247), on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shenzhen Edge Medical FY2025 operating loss narrows 59.4% to RMB89 million; revenue more than doubled to RMB456 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShenzhen Edge Medical FY2025 operating loss narrows 59.4% to RMB89 million; revenue more than doubled to RMB456 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-27 23:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Shenzhen Edge Medical FY2025 operating loss narrows 59.4% to RMB89 million; revenue more than doubled to RMB456 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Edge Medical published an annual results announcement, reporting revenue of RMB455.7 million and gross profit of RMB300.7 million.\n        </li>\n<li>\n          Revenue more than tripled by 184.8%, which the company attributed to rapid growth in surgical robot sales in domestic and overseas markets.\n        </li>\n<li>\n          Gross margin was 66.0%, up 4.7 percentage points, reflecting cost management and improved production efficiency.\n        </li>\n<li>\n          Loss attributable to equity shareholders was RMB88.6 million, narrowing by 59.4%, driven mainly by higher sales volume of the Edge Multi-Port Endoscopic Surgical Robot.\n        </li>\n<li>\n          Adjusted net loss was RMB20.5 million, narrowing by 88.5%, while cash and cash equivalents were RMB86.0 million.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Edge Medical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260327-12075247), on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1100","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL13V33C:1","article_id":"2622732518","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622732518","pubTimestamp":1774623914,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Edge Medical published an annual results announcement, reporting revenue of RMB455.7 million and gross profit of RMB300.7 million.Revenue more than tripled by 184.8%, which the company attributed to rapid growth in surgical robot sales in domestic and overseas markets.Gross margin was 66.0%, up 4.7 percentage points, reflecting cost management and improved production efficiency.Loss attributable to equity shareholders was RMB88.6 million, narrowing by 59.4%, driven mainly by higher sales volume of the Edge Multi-Port Endoscopic Surgical Robot.Adjusted net loss was RMB20.5 million, narrowing by 88.5%, while cash and cash equivalents were RMB86.0 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Edge Medical Co. Ltd. publi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1100":"医疗保健设备","02675":"精锋医疗-B"},"translate_title":"深圳边缘医疗2025财年经营亏损收窄59.4%至人民币89百万元；收入增长逾一倍至人民币4.56亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02675":0.9},"content_text":"Shenzhen Edge Medical FY2025 operating loss narrows 59.4% to RMB89 million; revenue more than doubled to RMB456 million\n    \n\n\n          Edge Medical published an annual results announcement, reporting revenue of RMB455.7 million and gross profit of RMB300.7 million.\n        \n\n          Revenue more than tripled by 184.8%, which the company attributed to rapid growth in surgical robot sales in domestic and overseas markets.\n        \n\n          Gross margin was 66.0%, up 4.7 percentage points, reflecting cost management and improved production efficiency.\n        \n\n          Loss attributable to equity shareholders was RMB88.6 million, narrowing by 59.4%, driven mainly by higher sales volume of the Edge Multi-Port Endoscopic Surgical Robot.\n        \n\n          Adjusted net loss was RMB20.5 million, narrowing by 88.5%, while cash and cash equivalents were RMB86.0 million.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Edge Medical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260327-12075247), on March 27, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622732518","isCrawlerRequest":true}